Open AccessCoexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report
Author(s) -
Xuebing Shi,
Jiang Ji-fa,
Fengxiang Jin,
Wenjun Cheng
Publication year - 2019
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v7.i9.1087
Subject(s) - medicine , essential thrombocythemia , polycythemia vera , myelofibrosis , myeloid leukemia , breakpoint , breakpoint cluster region , mutation , thrombocytosis , imatinib mesylate , abl , cancer research , janus kinase 2 , imatinib , bone marrow , genetics , chromosomal translocation , tyrosine kinase , biology , gene , platelet , receptor
The Janus kinase 2 ( JAK2 ) V617F mutation is common in patients with breakpoint cluster region-Abelson1 ( BCR-ABL1 )-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis, but is rarely detected in BCR-ABL1- positive chronic myeloid leukemia (CML) patients. Here, we report a CML patient with both a BCR-ABL1 rearrangement and JAK2 V617F mutation.